The price of Caprolactam followed downturn in December xxxx and extended into the first week of January xxxx in the US. This downward movement can be attributed to weak demand conditions and an ample flow of material in the market.
In December, the US manufacturing sector experienced a further contraction, marked by a decline in output and an acceleration in the downturn of new orders. The feedstock benzene remained weak, supporting the production cost of Caprolactam in the domestic market. Reduced total new sales reflected weaknesses in both domestic and external demand, prompting firms to adjust their input buying and hiring activities accordingly. Signs of increased spare capacity were evident through a faster decline in backlogs and destocking, as companies sought to better manage cash flow. Many businesses cited weak client demand, attributing it to lower purchasing power among customers and global economic uncertainty. Orders from...
